No abstract

The global evolution of the SARS-CoV-2 virus is known to all. The diagnosis of SARS-CoV-2 pneumonia is expected to worsen, and mortality will be higher when combined with myocardial injury (MI). The combination of novel coronavirus infections in patients with MI can cause confusion in diagnosis and assessment, with each condition exacerbating the other, and increasing the complexity and difficulty of treatment. It would be a formidable challenge for clinical practice to deal with this situation. Therefore, this review aims to gather literature on the progress in managing MI related to SARS-CoV-2 pneumonia. This article reviews the definition, pathogenesis, clinical evaluation, management, and treatment plan for MI related to SARS-CoV-2 pneumonia based on the most recent literature, diagnosis, and treatment trial reports. Many studies have shown that early diagnosis and implementation of targeted treatment measures according to the different stages of disease can reduce the mortality rate among patients with MI related to SARS-CoV-2 pneumonia. The reviewed studies show that multiple strategies have been adopted for the management of MI related to COVID-19. Clinicians should closely monitor SARS-CoV-2 pneumonia patients with MI, as their condition can rapidly deteriorate and progress to heart failure, acute myocardial infarction, and/or cardiogenic shock. In addition, appropriate measures need to be implemented in the diagnosis and treatment to provide reasonable care to the patient.

The purpose of this rapid review is to investigate the development of the hepatic manifestations and challenges with SARS-COV-2 and multiple viral hepatitis infections. The literature on the most critical viral, genetic and immunological factors between SARS-CoV-2 and viral hepatitis was reviewed, and the most important interactions that occur with the host were identified in addition to the use of antivirals, another drug, and also the potential of defective viral genomes in antiviral inhibitors. This review specified that some types of viral hepatitis in SARS-COV-2 patients may be reduced reactivation and receive immunosuppressive therapy. We concluded from the current review that it is necessary to consider the special care of persons exposed to infection with SARS-CoV-2 to persons infected with viral hepatitis. In particular, advanced cases of the disease and their stages of treatment as it leads to liver dysfunction and life-threatening patient.

No abstract

No abstract

No abstract

Infection with the hepatitis B virus can lead to asymptomatic carrier status, developing into severe chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Ten genotypes (A-J) and 46 sub-genotypes have been discovered. As a result, the current study was conducted to determine HBV genotypes in Iraqi patients. RT-PCR was used to determine the highest viral load in infected subjects and then used for screening HBV genotyping. The results showed that HBV genotype distribution among HBV infected patients was as follows: genotypes C, A, B, and D (8.5%, 5%, 4.3%, and 2.1%, respectively). In addition, the value of the viral load was higher with genotype C compared to A, B, and D HBV genotyping. This study concluded that mono-genotypes prevalent in patients infected with HBV and genotype C were more prevalent. In addition to the existence of a relationship between viral load and genotyping.